Compare INSE & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INSE | SGMT |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | United States | United States |
| Employees | 1020 | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.5M | 169.4M |
| IPO Year | 2014 | 2021 |
| Metric | INSE | SGMT |
|---|---|---|
| Price | $6.57 | $7.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $14.00 | ★ $26.13 |
| AVG Volume (30 Days) | 144.4K | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $199,800,000.00 | $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.26 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 30.25 | N/A |
| 52 Week Low | $6.11 | $4.50 |
| 52 Week High | $9.95 | $11.41 |
| Indicator | INSE | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 32.66 | 58.62 |
| Support Level | $6.29 | $7.04 |
| Resistance Level | $8.57 | $8.80 |
| Average True Range (ATR) | 0.43 | 0.50 |
| MACD | -0.13 | 0.03 |
| Stochastic Oscillator | 4.76 | 74.60 |
Inspired Entertainment Inc is a gaming technology company, supplying content, platform and other products and services to licensed online and land-based lottery, betting and gaming operators of various countries through a range of distribution channels, on a business-to-business basis. The company provides digital gaming solutions (i) on its own proprietary and secure network, which accommodates a wide range of devices, including land-based gaming machine terminals, mobile devices and online computer applications, and (ii) through third party networks. It operates in four business segments: Gaming, Virtual Sports, Interactive and Leisure. The majority of revenue is derived from the Leisure Segment, which includes the supply of the gaming and amusement machines.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.